SCHEMBL3349980

SCHEMBL3349980

CCOC(=O)N1CCc2c(sc(NC(=O)C=Cc3cccc(OC)c3OC)c2C#N)C1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.53
ALDH1A1 P00352 6/20 0.53
SMN1; SMN2 Q16637 3/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
MEN1 O00255 7/20 0.52
KMT2A Q03164 7/20 0.52
TP53 P04637 2/20 0.52
LMNA P02545 2/20 0.52
HSD17B10 Q99714 2/20 0.52
TSHR P16473 1/20 0.52
NPSR1 Q6W5P4 1/20 0.52
TGFBR1 P36897 2/20 0.51
KDM4E B2RXH2 3/20 0.49
GAA P10253 3/20 0.49
POLB P06746 3/20 0.46
HTT P42858 1/20 0.45
RECQL P46063 1/20 0.45
GRM1 Q13255 1/20 0.44
THRB P10828 1/20 0.44
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13166079 1.00 MAPT (0.53) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL13166194 0.96 MAPT (0.53) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3356483 0.96 MAPT (0.53) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL13166091 0.93 MAPT (0.54) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3572132 0.93 MAPT (0.54) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL3349925 0.93 TGFBR1 (0.55) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL13166083 0.93 TGFBR1 (0.55) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL4603728 0.91 MAPT (0.56) MAPTALDH1A1SMN1; SMN2MEN1KMT2A
SCHEMBL3353493 0.91 MEN1 (0.56) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1
SCHEMBL13166215 0.91 MEN1 (0.56) MAPTALDH1A1SMN1; SMN2L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7803945-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-09-28 US claimed
EP-1753512-B1 TETRAHYDROPYRIDOTHIOPHENES NYCOMED GMBH (DE) 2008-07-09 EP claimed
US-7723523-B2 Tetrahydropyridothiophenes 4SC AG (DE) 2010-05-25 US disclosed
EP-1753512-B1 TETRAHYDROPYRIDOTHIOPHENES NYCOMED GMBH (DE) 2008-07-09 EP disclosed
US-20070244112-A1 Novel tetrahydropyridothiophenes ALTANA PHARMA AG (DE) 2007-10-18 US disclosed
EP-1753512-A2 TETRAHYDROPYRIDOTHIOPHENES Altana Pharma AG (DE) 2007-02-21 EP disclosed
WO-2005118071-A2 TETRAHYDROPYRIDOTHIOPHENES ALTANA PHARMA AG (DE) 2005-12-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070244112-A1 Novel tetrahydropyridothiophenes BAX, BCL2, BAD MAPT 1192/4885ALDH1A1 683/4885SMN1; SMN2 3331/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.